Calvet Xavier, Carpio Daniel, Rodríguez-Lago Iago, García-Vicuña Rosario, Barreiro-de-Acosta Manuel, Juanola Xavier, Aguas Mariam, Castillo Concepción, Gratacós Jordi
Servicio del Aparato Digestivo, Hospital Universitario Parc Taulí, Departamento de Medicina, Universidad Autónoma de Barcelona, CIBERehd, Instituto de Salud Carlos III. Parc Taulí, Sabadell, Barcelona, España.
Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Complexo Hospitalario Universitario de Pontevedra, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Pontevedra, España.
Gastroenterol Hepatol. 2021 Oct;44(8):587-598. doi: 10.1016/j.gastrohep.2021.01.007. Epub 2021 Feb 25.
Patients with certain immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), have an increased risk of severe infectious diseases than the general population, which are mainly associated with the immunosuppressive treatments that they receive. These treatments act on the immune system through different mechanisms, causing different degrees of immunosuppression and a variable risk depending on whether the pathogen is a virus, bacteria or fungus. This article reviews the most relevant literature on the subject, which was selected and discussed by a panel of experts. The aim of this article is to review the risk of infections in patients with IBD and RA, and the potential preventive measures.
患有某些免疫介导的炎症性疾病的患者，如类风湿性关节炎（RA）和炎症性肠病（IBD），比普通人群患严重传染病的风险更高，这主要与他们接受的免疫抑制治疗有关。这些治疗通过不同机制作用于免疫系统，根据病原体是病毒、细菌还是真菌，会导致不同程度的免疫抑制和不同的风险。本文回顾了该主题的最相关文献，这些文献由一个专家小组挑选和讨论。本文的目的是回顾IBD和RA患者的感染风险以及潜在的预防措施。
